查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
乳腺病变定位市场 - 增长、趋势、COVID-19 影响和预测 (2023-2028)
市场调查报告书
商品编码
1190148

乳腺病变定位市场 - 增长、趋势、COVID-19 影响和预测 (2023-2028)

Breast Lesion Localization Methods Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 100 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

在预测期内，乳腺病变定位市场预计将以 11.2% 的复合年增长率增长。

COVID-19 大流行严重影响了所研究的市场，大流行导致的封锁和非紧急程序的暂停导致医院、诊所和诊断中心的就诊人数显着下降。我是。 根据 2021 年 10 月发表在《预防医学》上的一项研究，全球乳腺癌筛查和参与受到了大流行的影响。 许多国家，包括加拿大、荷兰、德国、意大利、英国和澳大利亚，已暂停乳腺癌筛查计划，以防止冠状病毒污染和人口传播。 因此，筛查和诊断的延误影响了大流行期间的市场增长。 然而，随着 COVID-19 限制的解除、肿瘤科和医院的重新开放、乳腺癌手术的增加以及政府对乳腺癌筛查和治疗的宣传计划，研究中的市场预计将在未来反弹增长三到四年。将是

推动市场增长的其他因素包括乳腺癌和乳腺癌手术患病率的上升、乳腺病变定位技术的进步，以及公众意识的提高和对乳腺癌早期发现的需求。

随着用于识别和治疗乳腺病变和乳腺癌的外科手术和成像技术的进步，乳腺病变定位已成为一种常见的程序。 由于全球乳腺癌负担不断增加，预计它将引领市场。 根据 GLOBOCAN 2020 报告，预计到 2040 年将诊断出约 3,025,471 例乳腺癌新病例。 随着乳腺癌患者数量的增加，对乳房定位手术的需求不断增加，推动了市场的增长。

政府加大力度提高公众对乳腺癌的认识，预计也会增加对乳腺癌诊断和治疗的需求。 2021 年 10 月，Wefralife 和德国粉红丝带 (NPO) 发起了“乳腺癌影响我们所有人”活动，以提高人们对乳腺癌的认识并普及乳房护理应用。 BreastCare 是一款免费的多语言应用程序，以 7 种语言提供与乳腺癌早期检测和预防相关的多媒体内容。

此外，乳房定位方法的技术不断进步为公司创造了机会，并增加了执行该程序的先进设备的可用性。 2021 年 5 月，美国 FDA 批准了 MOLLI Surgical 用于乳腺癌手术的新型无线立体定向技术，使放射科医生能够快速准确地标记病灶，帮助外科医生高效地定位和切除病灶。 这个新平台包括可植入标记物、检测棒和可视化平板电脑，以帮助改善肿瘤定位。

因此，由于乳腺癌负担增加、政府举措增加和产品批准等因素，预计在预测期内会增长。 然而，诸如严格的监管指南和与乳腺病变定位方法相关的高成本等因素预计将阻碍预测期内的市场增长。

主要市场趋势

电线本地化部分有望占据重要的市场份额

在乳腺病变定位方面，由于人口增长导致乳腺癌发病率上升、技术先进的产品增加以及产品发布增加等因素，在预测期内，线材定位领域将出现显着增长。

与其他乳腺病变定位技术相比，钢丝定位还具有价格低廉、准确且有效的优势，有望在乳腺癌治疗中得到越来越多的采用。 预计这也将对该领域的增长产生积极影响。

钢丝定位法是定位乳房肿块和异常的最广泛使用的方法。 这种方法使用一根细线来精确定位肿块或异常的确切位置。 又称间苗法或针状法。 2021 年 2 月发表在 Journal of Personalized Medicine 上的一篇论文证实，导线定位方法可以在不同类型的成像引导下（乳房 X 线摄影、超声、磁共振成像）进行。 该手术是治疗不可触及的乳腺病变最常见的手术，据报导清洁边缘为 70.8% 至 87.4%。 预计此类研究将增加乳腺癌患者治疗的采用率，并促进该领域的增长。

乳腺癌负担的增加、乳房手术数量的增加以及导丝定位方法在诊断和治疗过程中的广泛采用是导丝定位领域的主要增长动力。 根据 2022 年 9 月发表在《乳腺癌研究与治疗》杂誌上的一篇论文，在 60 岁以上的女性中，德国 175 厘米以上女性的乳腺癌患病率为 6.8%，171-175 厘米女性的乳腺癌患病率为 12.2%。说是%。 由于乳腺癌患者的高负担，早期发现和有效治疗的需求不断增加，预计将进一步推动该细分市场的增长。

此外，对采用关键战略进入市场的公司的更多关注也有助于市场增长。 例如，2021 年 1 月，Hologic, Inc. 以 6400 万美元收购了 Somatex Medical Technologies。 此次收购将帮助该公司提供更广泛的创新乳腺健康解决方案，并通过活检部位标记和定位技术扩展其乳腺标记产品组合。 此外，通过此次收购，公司将扩大其在德国的直销渠道及其区域和全球分销商网络，并加强其在欧洲的销售队伍。

因此，由于上述因素（例如女性乳腺癌患病率较高以及线定位技术的采用率增加），预计研究领域在预测期内将会增长。

北美有望主导市场

北美在过去几年一直主导着乳腺病变定位市场，预计在预测期内也将呈现类似的趋势。 这主要是由于乳腺癌患者的高负担、强大的医疗保健基础设施和对乳腺癌的认识不断提高。

在北美，由于乳腺癌的高患病率和发病率、稳健的医疗保健基础设施以及更好的报销方案，预计美国在预测期内将占据所研究市场的很大份额。 根据 BCRF 发布的 2022 年统计数据，预计 2022 年美国女性将诊断出约 287,850 例乳腺癌新病例。 根据同一消息来源，在美国，女性在其生命中的某个阶段患上乳腺癌的平均风险为 13%。 近年来，美国乳腺癌的发病率每年增加0.5%。 根据加拿大癌症协会发布的 2022 年统计数据，预计到 2022 年将有大约 28,600 名加拿大女性被诊断出患有乳腺癌。 因此，预计乳腺癌患者的增加将推动对治疗乳腺癌的诊断和外科手术的需求，推动乳腺病变定位市场的增长多年。

此外，该地区不断增加的产品批准预计将增加市场上本地化设备的可用性，从而推动预测期内的市场增长。 例如，2022 年 7 月，Merit Medical System 将招募其首位患者参加上市后观察研究，以证明 SCOUT 的好处，SCOUT 是一种用于标记乳腺肿瘤、活检部位和淋巴结的无线雷达引导立体定位设备。

因此，由于上述因素（例如该地区的高乳腺癌负担和产品批准增加），预计研究市场将在预测期内增长。

竞争格局

乳腺病变定位市场是整合的，由几家主要参与者组成。 就份额而言，一些主要参与者目前主导着市场。 研究的市场参与者包括 Becton、Dickinson and Company、Hologic Inc.、Cook Medical、Merit Medical 和 STAYLABS。

其他好处

  • Excel 格式的市场预测 (ME) 表
  • 三个月的分析师支持

内容

第1章介绍

  • 调查先决条件和市场定义
  • 调查范围

第2章研究方法论

第 3 章执行摘要

第4章市场动态

  • 市场概览
  • 市场驱动力
    • 乳腺癌发病率和乳腺癌手术的增加
    • 乳腺病变定位的技术进步
    • 人们越来越意识到早期发现乳腺癌的必要性
  • 市场製约因素
    • 与乳腺病变定位方法相关的高成本
    • 严格的监管要求
  • 行业吸引力 - 波特五力分析
    • 新进入者的威胁
    • 买家的议价能力
    • 供应商的议价能力
    • 替代品的威胁
    • 竞争公司之间的敌对关係

第 5 章市场细分（金额基础：百万美元）

  • 通过本地化方法
    • 电线定位
    • 放射性同位素
    • 定位磁性示踪剂
    • 其他本地化方法
  • 按地区列出
    • 北美
      • 美国
      • 加拿大
      • 墨西哥
    • 欧洲
      • 德国
      • 英国
      • 法国
      • 意大利
      • 西班牙
      • 其他欧洲地区
    • 亚太地区
      • 中国
      • 日本
      • 印度
      • 澳大利亚
      • 韩国
      • 其他亚太地区
    • 中东和非洲
      • 海湾合作委员会
      • 南非
      • 其他中东地区
    • 南美洲地区
      • 巴西
      • 阿根廷
      • 其他南美洲

第6章竞争格局

  • 公司简介
    • Becton, Dickinson and Company
    • Hologic Inc.（SOMATEX Medical Technologies）
    • Cook Medical
    • Merit Medical（Cianna Medical）
    • STERYLAB SRL
    • Danaher Corporation（Leica Biosystems）
    • Theragenics Corporation（CP Medical Inc.）
    • Elucent Medical
    • Tsunami SRL
    • MDL SRL
    • MOLLI Surgical
    • Argon Medical Devices
    • Mermaid Medical A/S

第7章 市场机会与今后动向

简介目录
Product Code: 67726

The breast lesion localization methods market is expected to register a CAGR of 11.2% during the forecast period.

The COVID-19 pandemic severely impacted the market studied, as footfall in hospitals, clinics, and diagnostics centers decreased significantly due to the pandemic-resultant lockdown and the suspension of non-urgent procedures. As per a research study published in Preventive Medicines in October 2021, global breast cancer screening and participation were impacted by the pandemic. Many nations, such as Canada, the Netherlands, Germany, Italy, United Kingdom, and Australia, halted their breast screening programs to prevent the contamination and transmission of coronavirus among the population. Thus, the delayed screening and diagnostic procedures impacted the market growth during the pandemic. However, with the released COVID-19 restrictions, reopened oncology care units and hospitals, as well as an increased number of breast cancer surgical procedures and growing awareness programs by the government regarding breast cancer screening and treatment, the studied market is expected to regain its growth over the next 3-4 years.

Other factors, such as the rising prevalence of breast cancer and breast cancer surgeries, technological advancements in breast lesion localization, and increasing awareness and need for early detection of breast cancer among the population, are boosting the market growth.

The localization of breast lesions has emerged as a common procedure with advancements in the surgical and imaging techniques used to identify and treat breast injuries or breast cancer over time. The increasing burden of breast cancer worldwide is expected to drive the market. According to GLOBOCAN 2020 report, about 3,025,471 new breast cancer cases are expected to be diagnosed by 2040. The anticipated increase in the number of people who have breast cancer raises the demand for breast lesion localization procedures, propelling the market growth.

The increasing government initiatives to raise awareness regarding breast cancer among the population are also expected to increase the demand for breast cancer diagnosis and treatment. In October 2021, Wefra Life and Pink Ribbon Germany (a non-profit organization) launched a Breast Cancer Affects Us All campaign to raise awareness about breast cancer and promote breast care applications among the population. Breast Care is a free multilingual app that provides multimedia content in seven different languages that cover all pertinent aspects of early breast cancer detection and prevention.

Furthermore, the rising technological advancements in breast lesion localization methods are creating opportunities for companies, along with increasing the availability of advanced devices for conducting procedures. In May 2021, United States FDA approved MOLLI Surgical's new wire-free localization technology for breast cancer surgery that allows radiologists to mark lesions rapidly and precisely and helps surgeons locate and remove lesions efficiently. This new platform includes an implantable marker, detection wand, and visualization tablet, which help improve tumor localization.

Therefore, factors such as the increasing burden of breast cancer, rising government initiatives, and approval of products are expected to grow over the forecast period. However, factors such as strict regulatory guidelines and high costs associated with breast lesion localization methods are expected to hinder the market's growth over the forecast period.

Key Market Trends

Wire Localization Segment Expected to Hold a Significant Market Share

The wire localization segment is expected to witness significant growth in the breast lesion localization methods market over the forecast period owing to factors such as the rising prevalence of breast cancer among the population, growing technologically advanced products, and rising product launches.

Additionally, the advantages offered by the wire localization method, such as being less expensive, more accurate, and more effective than other breast lesion localization techniques, are also expected to increase its adoption during breast cancer treatment. This factor is also expected to impact the growth of the segment positively.

The wire localization method is the most widely used procedure for locating lumps or abnormalities in the breast. This procedure involves using a fine wire to determine the lump's or abnormality's exact location. It is also known as the fine-wire or needle localization method. As per an article published in the Journal of Personalized Medicine in February 2021, it has been observed that wire localization procedures can be performed under different kinds of image guidance (mammographic, sonographic, and magnetic resonance imaging). This procedure is the most common technique for non-palpable breast lesions, with clean margins reported between 70.8% and 87.4%. Such research is expected to increase its adoption for treating breast cancer among patients, thereby boosting segment growth.

The growing burden of breast cancer, an increasing number of breast surgeries, and the wide adoption of the wire localization method in diagnostic and treatment procedures are major growth factors for the wire localization segment. According to an article published in the Breast Cancer Research and Treatment in September 2022, in women aged 60 years and above, the prevalence of breast cancer in Germany was 6.8% in women above 175 cm in height and 12.2% in women with a height of 171-175 cm. The high burden of breast cancer cases increases the demand for early detection and effective treatment, which is further anticipated to fuel the segment's growth.

Furthermore, the companies' rising focus on adopting key strategies to enter the market contributes to market growth. For instance, in January 2021, Hologic, Inc. acquired Somatex Medical Technologies for USD 64 million. This acquisition assists the company in providing a broad suite of innovative breast health solutions and expanding its breast marker portfolio with biopsy site markers and localization technologies. Furthermore, with this acquisition, the company intends to boost its sales presence in Europe by growing its direct channel in Germany and its regional and global distributor partner network.

Thus, the studied segment is anticipated to grow over the forecast period due to the aforementioned factors, such as the high prevalence of breast cancer among women and the increasing adoption of wire localization methods.

North America Expected to Dominate the Market

North America held a significant share of the breast lesion localization methods market in the past few years and is expected to show a similar trend over the forecast period. This is primarily due to the high burden of breast cancer cases coupled with robust healthcare infrastructure and increasing awareness about breast cancer.

In North America, United States is expected to hold a significant share during the forecast period in the market studied due to the high prevalence and incidence of breast cancer, robust healthcare infrastructure, and better reimbursement scenarios. The 2022 statistics published by BCRF expected about 287,850 new cases of breast cancer to be diagnosed in women in United States in 2022. As per the same source, in United States, the average risk of women developing breast cancer at some point in their lives is 13%. In recent years, the incidence rate of breast cancer has increased by 0.5% per year in United States. Additionally, per 2022 statistics published by the Canadian Cancer Society, about 28,600 Canadian women are expected to be diagnosed with breast cancer in 2022. Thus, the anticipated increase in breast cancer cases fuels the demand for diagnostics and surgical procedures for treating breast cancer and drives the growth in the breast lesion localization methods market over the years.

Furthermore, the rising product approvals in the region increase the availability of localization devices in the market, which is anticipated to boost market growth over the forecast period. For instance, in July 2022, Merit Medical System enrolled the first patient in a post-market, observational study to demonstrate the benefits of SCOUT, a wireless, radar-guided localization system for marking breast tumors, biopsy sites, and lymph nodes.

Thus, the studied market is expected to grow over the forecast period due to the aforementioned factors, such as the high burden of breast cancer and increasing product approvals in the region.

Competitive Landscape

The breast lesion localization methods market is consolidated and consists of a few major players. In terms of share, a few of the major players are currently dominating the market. Some of the players in the market studied are Becton, Dickinson and Company, Hologic Inc., Cook Medical, Merit Medical, and STERYLABS, among others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions & Market Definition
  • 1.2 Scope Of The Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Prevalence of Breast Cancer and Breast Cancer Surgeries
    • 4.2.2 Technological Advancements in Breast Lesion Localization
    • 4.2.3 Increasing Awareness of Need for Early Detection of Breast Cancer
  • 4.3 Market Restraints
    • 4.3.1 High Costs Associated with Breast Lesion Localization Methods
    • 4.3.2 Stringent Regulatory Requirements
  • 4.4 Industry Attractiveness - Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD Million)

  • 5.1 By Localization Method
    • 5.1.1 Wire Localization
    • 5.1.2 Radioisotope Localization
    • 5.1.3 Magnetic Tracers Localization
    • 5.1.4 Other Localization Methods
  • 5.2 By Geography
    • 5.2.1 North America
      • 5.2.1.1 United States
      • 5.2.1.2 Canada
      • 5.2.1.3 Mexico
    • 5.2.2 Europe
      • 5.2.2.1 Germany
      • 5.2.2.2 United Kingdom
      • 5.2.2.3 France
      • 5.2.2.4 Italy
      • 5.2.2.5 Spain
      • 5.2.2.6 Rest of Europe
    • 5.2.3 Asia-Pacific
      • 5.2.3.1 China
      • 5.2.3.2 Japan
      • 5.2.3.3 India
      • 5.2.3.4 Australia
      • 5.2.3.5 South Korea
      • 5.2.3.6 Rest of Asia-Pacific
    • 5.2.4 Middle East and Africa
      • 5.2.4.1 GCC
      • 5.2.4.2 South Africa
      • 5.2.4.3 Rest of Middle East and Africa
    • 5.2.5 South America
      • 5.2.5.1 Brazil
      • 5.2.5.2 Argentina
      • 5.2.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Becton, Dickinson and Company
    • 6.1.2 Hologic Inc. (SOMATEX Medical Technologies)
    • 6.1.3 Cook Medical
    • 6.1.4 Merit Medical (Cianna Medical)
    • 6.1.5 STERYLAB SRL
    • 6.1.6 Danaher Corporation (Leica Biosystems)
    • 6.1.7 Theragenics Corporation (CP Medical Inc.)
    • 6.1.8 Elucent Medical
    • 6.1.9 Tsunami SRL
    • 6.1.10 MDL SRL
    • 6.1.11 MOLLI Surgical
    • 6.1.12 Argon Medical Devices
    • 6.1.13 Mermaid Medical A/S

7 MARKET OPPORTUNITIES AND FUTURE TRENDS